The high expression of MMP1 has been confirmed in various types of cancers, indicating poorer overall survival rates, and showing significant negative correlations with the quantities of CD8+ T cells, CD4+ T cells, and macrophage infiltration, suggesting MMP1 as a potential novel biomarker for immunotherapy (75, 76). This evidence concerns the gene CD8A and cancer.